Growth hormone and health policy.
GH treatment for short children is representative of many frontline issues in health care policy. In this paper, we highlight key policy issues exemplified by GH, focusing on pharmaceutical innovation, insurance coverage and pricing, and physician decisions, and we discuss their implications for endocrinology and GH use.
Cuttler
Leona
L
Division of Pediatric Endocrinology, Diabetes, and Metabolism and The Center for Child Health and Policy, Rainbow Babies and Children's Hospital, Room 737, Case Western Reserve University, 11100 Euclid Avenue, Cleveland,OH 44106, USA. leona.cuttler@case.edu
Silvers
J B
JB
D003695:Delivery of Health Care / Q000191:economics; D055808:Drug Discovery / Q000191:economics; D006130:Growth Disorders / Q000191:economics* / Q000628:therapy; D006291:Health Policy / Q000191:economics*; D019382:Human Growth Hormone / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019458:Insurance Coverage / Q000191:economics; D010818:Practice Patterns, Physicians' / Q000191:economics; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use
D011994:Recombinant Proteins; D019382:Human Growth Hormone